Skip to content Skip to footer
Subscribe Now
Disease of the Month: IgA Nephropathy
INSIGHTS+

Disease of the Month: IgA Nephropathy

Shots: To create a wholesome environment for the current and the future generation, it’s totally up to life science companies and decision-makers to embrace and integrate every prospect of the underlying disease conditions and address those issues to find cures PharmaShots brings this month an informative take on the disease IgA nephropathy Often known as…
March 13, 2023

Read more

VIEWPOINTS_Nirja Patel_2023
VIEWPOINTS

Nirja Patel, Senior International Product Manager at Roche Shares her Views on the US FDA Approval of the PATHWAY anti-HER2 Test

Shots:  Nirja gave the details of the PATHWAY anti-HER2 (4B5) to identify metastatic breast cancer patients with low HER2 expression through its scoring algorithm that helps pathologists to identify “low expressors” of HER2  She told PharmaShots about how this test is able to identify patients who may benefit from Enhertu as a treatment option. She…
March 7, 2023

Read more

Exclusive_Iris Loew-Friedrich_2023
EXCLUSIVE

Iris Loew-Friedrich, CMO and Head of Development Solutions at UCB Shares her Thoughts on the Launch of New Innovators Campaign

Shots: Iris shared the specifics of the launch of the UCB’s Innovators campaign. The campaign spotlights the R&D employees’ perspectives on innovation and aims to highlight why innovation is a key driving force at UCB for bettering the lives of patients She gave her thoughts on how UCB is adopting innovative AI programs that use…
March 6, 2023

Read more

VIEWPOINTS_Jason-Winnike_2023
VIEWPOINTS

Jason Winnike, Study Director at Metabolon Shares Insights from the Launch of its Oxysterol Targeted Panel

Shots: Jason shared his views on the launch of Metabolon, Inc.’s new Oxysterols Targeted Panel, highlighting its key features  He told how the panel measures 12 oxysterols and related sterols of biological significance to identify biomarkers for the prediction and early detection of cardiovascular diseases, neurodegenerative diseases, and cancer  The interview gives a profound understanding…
March 6, 2023

Read more

VIEWPOINTS_Zack Usilton_2023
VIEWPOINTS

Zack Usilton, Chief Development Officer at Senta Partners Shares Insights from their Partnership with Reston ENT to Expand its Network of ENT Practices

Shots:   Zack Usilton spoke about their partnerships with Reston ENT. He also elaborated on their past collaborations with some of the allergy groups He also spoke on how these alliances will help Senta Partners to expand its footprint across 57 locations in 5 states in the Mid-Atlantic region   The interview gives an understanding of Senta…
March 2, 2023

Read more

Insights+ Key Biosimilars Events of February 2023
INSIGHTS+

Insights+ Key Biosimilars Events of February 2023

Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of February, Alvotech entered into a commercialization agreement…
March 1, 2023

Read more

VIEWPOINTS_Laura Niklason_2023
VIEWPOINTS

Laura Niklason, Founder, President, and CEO of Humacyte Shares her Views from the HAV™ Coronary Artery Bypass Graft Data Presented at the AHA Scientific Sessions 2022

Shots:  Laura gave an overview of Human acellular vessels (HAV). She talked about the six-month results of the HAV in a non-human primate model of CABG presented at the annual American Heart Association (AHA) Scientific Sessions 2022  She also elaborated on the construction and development of the CABG model and how it treats blocked arteries…
February 28, 2023

Read more

VIEWPOINTS_Steffen-Sebastian Bolz_2023
VIEWPOINTS

Steffen-Sebastian Bolz, CSO of Aphaia Pharma Shares Insights from the P-II Study for Chronic Weight Management in Individuals with Obesity

Shots:  Steffen shared the details of the first patient enrolled in the P-II study of Aphaia Pharma’s lead product APH-012 to induce weight loss in individuals with obesity  He briefed the PharmaShots team about the study design of the P-II trial and also elaborated on the results from the P-I study The interview shows how…
February 27, 2023

Read more

Exclusive Coverage Global PHT Expo & Summit 2023
EVENTS

Exclusive Coverage: Global PHT Expo & Summit 2023

The 15th and 16th of February saw the Global PHT Expo & Summit taking place at the Hyatt Centric in New Delhi, India. Through Global PHT Summit, it was for the first time that the pharma, healthcare, and technology veterans, pioneers, and professionals converged on the same platform to impart their knowledge on the best & futuristic PHT practices. The theme of the event…
February 27, 2023

Read more

Load more